Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metabolic-Associated Steatotic Liver Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 0 results

Not applicableNot Yet RecruitingNCT06871930
What this trial is testing

Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease

Who this might be right for
Hepatocellular Carcinoma (HCC)
Assiut University 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT07726693
What this trial is testing

Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial

Who this might be right for
Liver Cirrhosis
University College, London 1,142
Not applicableUnknownNCT06536933
What this trial is testing

Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees

Who this might be right for
Metabolic Dysfunction-Associated Steatotic Liver Disease
Sohag University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT07024212
What this trial is testing

Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

Who this might be right for
MASLD
Zhejiang Doer Biologics Co., Ltd. 110
Not applicableLooking for participantsNCT07440511
What this trial is testing

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

Who this might be right for
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 500
Large-scale testing (Phase 3)Active Not RecruitingNCT06161571
What this trial is testing

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Who this might be right for
NASH/MASHNAFLD/MASLD
Akero Therapeutics, Inc 700